

In the Claims

Please amend Claims 1, 5, 7, 10, 11, 16, 17, 20, 28 and 32 as follows:

- Sub F1
1. (Amended) A retroviral vector which undergoes promoter conversion comprising in 5' to 3' order,
- a) a 5' long terminal repeat region of the structure U3-R-U5;
 - b) one or more sequences selected from coding and non-coding sequences, said sequences being inserted into the body of the vector; and
 - c) a 3' long terminal repeat region comprising a partially deleted U3 region wherein in said partially deleted U3 region [comprises] a polylinker sequence containing a heterologous promoter [not related to the retroviral vector] is inserted, said promoter regulating, after infection of [the] a target cell, expression of [at least] said one [of the] or more sequences selected from coding and non-coding sequences [being inserted into the body of the vector].

- F2
5. (Amended) The retroviral vector according to Claim 1, wherein said heterologous DNA fragment [is selected from the group consisting of] further comprises a regulatory [elements, promoters and combinations thereof] element other than a promoter.

Sub F2
F3

(Amended) The retroviral vector according to Claim 31, wherein [the] said regulatory element[s and promoters are] is selected from the group consisting of Whey Acidic Protein specific regulatory elements and promoters, Mouse Mammary Tumor Virus specific regulatory elements and promoters, β -lactoglobulin and casein specific regulatory elements and promoters, pancreas specific regulatory elements and promoters, lymphocyte specific regulatory elements and promoters, Mouse Mammary Tumor Virus specific regulatory elements and promoters conferring responsiveness to glucocorticoid hormones or directing expression to the mammary gland, and combinations thereof.

- F4
10. (Amended) The retroviral vector according to Claim 1, wherein said retroviral vector is [based on] derived from a BAG vector.

- E5
11. (Amended) The retroviral vector according to Claim 1, wherein [said] the coding sequence is selected from the group consisting of marker genes, therapeutic genes, antiviral genes, antitumor genes, cytokine genes and combinations thereof.

- E6
16. (Amended) The retroviral vector according to Claim 5, wherein said regulatory element[s] is regulatable by transacting molecules.

E7 3/27

(Amended) A retroviral vector kit comprising:

a retroviral vector which undergoes promoter conversion comprising in 5' to 3' order, a) a 5' long terminal repeat region of the structure U3-R-U5; b) one or more sequences selected from coding and non-coding sequences, said sequences being inserted into the body of the vector; and c) a 3' long terminal repeat region comprising a partially deleted U3 region wherein in said partially deleted U3 region [comprises] a polylinker sequence containing a heterologous promoter [not related to the retroviral vector] is inserted, said promoter regulating, after infection of [the] a target cell, expression of [at least] said one [of the] or more sequences selected from coding and non-coding sequences [being inserted into the body of the vector]; and

(

a packaging cell line harboring at least one retroviral or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.

E8 3/27

20. (Amended) A method for introducing homologous or heterologous nucleotide sequences into [target human or animal cell populations comprising cells of a human or an animal, or isolated cultured] cells of a human or an animal, said method comprising infecting the [target] cells [population] with recombinant retroviruses produced by the producer cell line of Claim 28.

E9 3/27

28. (Amended) A producer cell line producing a retroviral particle, the producer cell comprising a retroviral vector and a DNA construct coding for proteins required for the retroviral vector to be packaged, said retroviral vector comprising in 5' to 3' order, a) a 5' long terminal repeat region of the structure U3-R-U5; b) one or more sequences selected